Standard Operating Procedure for Regulatory Escalation and Issue Management
| Department | Regulatory Affairs |
| SOP No. | RA/2026/787 |
| Supersedes | NA |
| Page No. | 1 of X |
| Issue Date | 17/04/2026 |
| Effective Date | 17/04/2026 |
| Review Date | 17/04/2028 |
Purpose
This Standard Operating Procedure (SOP) establishes a clear and consistent process for identifying, escalating, and managing regulatory issues to ensure timely resolution and maintain compliance with applicable laws, guidelines, and internal quality standards. The control objective is to prevent regulatory non-compliance and its impact on product quality, patient safety, and business continuity by enforcing structured escalation and issue management practices within the organization.
Scope
This SOP applies to all regulatory affairs activities, documentation, cross-functional coordination, and communication processes related to regulatory submissions and compliance monitoring across all departments. It encompasses identification, assessment, and escalation of regulatory deviations, inquiries, inspections, submissions, and other compliance-related issues involving any dosage form, product, equipment, or system. The SOP excludes technical investigations unrelated to regulatory compliance and internal departmental administrative matters unless linked to regulatory risk.
Responsibilities
- Regulatory Affairs Team: Identify, document, and initially assess regulatory issues; initiate escalation as per procedure.
- Quality Assurance: Review regulatory issues for impact on quality systems and advise on corrective actions.
- Departmental Heads: Support issue investigation and provide timely information for resolution.
- Compliance Officer: Monitor adherence to regulatory requirements and assist in issue management oversight.
- Senior Management: Review escalated issues and approve necessary strategic responses and resource allocation.
Accountability
The Head of Regulatory Affairs is accountable for ensuring implementation, compliance, periodic review, and effectiveness of this SOP. This includes oversight of issue escalation, ensuring issues are resolved in a timely manner, regulatory notifications are made as required, and lessons learned are incorporated into ongoing process improvements.
Procedure
The procedure for regulatory escalation and issue management is designed for effective control within a regulated pharmaceutical environment. The key steps are described below:
1. Identification and Documentation: All regulatory-related issues, such as non-conformances, inspection observations, regulatory queries, or potential compliance risks discovered via inspections, audits, internal reviews or operational activities must be promptly identified and documented in the Regulatory Issue Log (Annexure-1).
2. Preliminary Assessment: Regulatory Affairs shall assess the issue’s potential impact on product quality, patient safety, regulatory submissions, and compliance obligations. If necessary, Quality Assurance and relevant department input shall be sought to determine risk classification (e.g., minor, major, critical).
3. Escalation Decision: Issues classified as major or critical, or those that potentially affect regulatory filing timelines or market approval, must be escalated immediately to Senior Management and the Compliance Officer. Minor issues shall be managed at department level, with oversight by Regulatory Affairs.
4. Investigation and Root Cause Analysis: Assigned cross-functional teams will investigate root causes, using documented methodologies such as CAPA or RCA tools, documented in investigation reports. The investigation scope must address regulatory impact clearly.
5. Corrective and Preventive Actions (CAPA): Based on findings, CAPAs shall be defined, implemented, and monitored for effectiveness. Compliance requirements for reporting to regulatory agencies must be verified, including timelines and formats.
6. Communication and Reporting: Timely communication to all stakeholders including regulatory authorities (if required), internal management, and affected departments is mandatory. Regulatory updates must be documented in correspondence logs (Annexure-2).
7. Review and Closure: After ensuring that CAPAs are effective and issue resolution verified, the Regulatory Affairs department will close the issue formally in the Issue Log, documenting closure rationale and approval.
8. Record Retention: All documentation related to the issue, investigation, CAPA, and communications must be securely retained as per the organization’s document control policy and regulatory requirements.
9. Periodic Review: Regulatory Affairs shall conduct periodic reviews of accumulated issues and trends to improve processes and prevent recurrence.
Throughout these stages, adherence to applicable Good Manufacturing Practices (GMP), data integrity principles, and confidentiality must be strictly maintained. All actions shall be traceable, authorized, and documented to withstand internal and external audits.
Abbreviations
- CAPA – Corrective and Preventive Actions
- GMP – Good Manufacturing Practices
- RCA – Root Cause Analysis
- RA – Regulatory Affairs
- QA – Quality Assurance
- SOP – Standard Operating Procedure
Documents
- Regulatory Issue Log (Annexure-1)
- Regulatory Communication and Correspondence Record (Annexure-2)
- Regulatory Escalation and Resolution Report Template (Annexure-3)
References
- ICH Q10 Pharmaceutical Quality System Guidelines
- FDA Guidance for Industry: Quality Systems Approach to Pharmaceutical CGMP Regulations
- EU GMP Annex 11 – Computerised Systems
- ICH Q9 Quality Risk Management
- Company Quality Management System Documentation and Regulatory Policies
Version
1.0
Approval
| Prepared By | |
| Checked By | |
| Approved By |
Annexures
Annexure-1: Regulatory Issue Log
Purpose: To systematically record and track all regulatory issues from identification through closure, ensuring controlled management and audit trail.
| Issue ID | Date Identified | Department | Issue Description | Impact Assessment | Risk Level | Escalated To | Status | Closure Date |
|---|---|---|---|---|---|---|---|---|
| RI-2026-001 | 10/04/2026 | Regulatory Affairs | Query received from agency regarding dossier inconsistency | Moderate impact on submission timeline | Major | Senior Management | Open | |
| RI-2026-002 | 12/04/2026 | Quality Assurance | Inspection observation on labeling deviation | Potential compliance risk | Critical | Compliance Officer | Under Investigation |
Annexure-2: Regulatory Communication and Correspondence Record
Purpose: To document all communications with regulatory authorities and internal stakeholders related to regulatory issues for transparency and audit purposes.
| Date | Issue ID | Sender/Receiver | Communication Type | Subject | Summary | Action Items |
|---|---|---|---|---|---|---|
| 11/04/2026 | RI-2026-001 | Regulatory Affairs / Agency | Dossier Data Query | Clarification on batch release data requested | Provide response by 20/04/2026 | |
| 13/04/2026 | RI-2026-002 | QA / Regulatory Affairs | Meeting Minutes | Labeling Non-compliance Discussion | Review labeling procedures and prepare CAPA | Initiate CAPA by 18/04/2026 |
Annexure-3: Regulatory Escalation and Resolution Report Template
Purpose: To capture detailed investigation, root cause analysis, corrective/preventive actions, and final resolution for escalated regulatory issues.
| Issue ID | RI-2026-002 |
| Date of Escalation | 12/04/2026 |
| Department | Quality Assurance |
| Issue Description | Inspection observation on labeling deviation |
| Investigation Summary | Root cause identified as outdated SOP on labeling checks |
| Corrective Actions | Revised labeling SOP and retraining of personnel completed |
| Preventive Actions | Established periodic SOP reviews and internal audits for labeling |
| Effectiveness Verification | Subsequent internal audit showed no deviations |
| Closure Date | 15/04/2026 |
| Approved By |
Revision History
| Revision Date | Revision No. | Revision Details | Reason for Revision | Approved By |
| 17/04/2026 | 1.0 | Initial issue | New SOP creation |